Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL371460 | 0.81 | DRD3 (0.31) | MEN1KMT2ACYP1A2CA12CA2 | |
| SCHEMBL371419 | 0.73 | BLM (0.43) | CYP1A2TSHRCYP3A4TDP1 | |
| SCHEMBL371406 | 0.71 | CYP1A2 (0.36) | MEN1KMT2ACYP1A2TSHRCYP3A4 | |
| SCHEMBL8811318 | 0.71 | MEN1 (0.40) | MEN1KMT2ACYP1A2TSHRPOLB | |
| SCHEMBL28676330 | 0.71 | MEN1 (0.44) | MEN1KMT2ACYP1A2CA12CA1 | |
| SCHEMBL3147520 | 0.69 | TDP1 (0.36) | MEN1KMT2AGAATSHRNPSR1 | |
| SCHEMBL8602788 | 0.68 | CPB2 (0.39) | MEN1KMT2ACYP1A2TSHRPOLB | |
| SCHEMBL282248 | 0.67 | TSHR (0.48) | GAATSHRCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL19792824 | 0.67 | CYP1A2 (0.41) | MEN1KMT2ACYP1A2TSHRPOLB | |
| SCHEMBL28876472 | 0.66 | TSHR (0.42) | GAATSHRCYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408790-A1 | METHODS FOR THE PREPARATION OF [2-(8,9-DIOXO-2,6-DIAZABICYCLO[5.2.0]NON-1(7)-EN-2-YL)ETHYL]PHOSPHONIC ACID AND PRECURSORS THEREOF | Wyeth LLC (US) | 2012-01-25 | — | — | EP | claimed |
| WO-2010108063-A1 | METHODS FOR THE PREPARATION OF [2-(8,9-DIOXO-2,6-DIAZABICYCLO[5.2.0]NON-1(7)-EN-2-YL)ETHYL]PHOSPHONIC ACID AND PRECURSORS THEREOF | WYETH LLC (US) | 2010-09-23 | — | — | WO | claimed |
| US-20120116074-A1 | METHODS FOR THE PREPARATION OF [2-(8,9-DIOXO-2,6-DIAZABICYCLO[5.2.0]NON-1(7)-EN-2-YL)ETHYL]PHOSPHONIC ACID AND PRECURSORS THEREOF | CULLEN THOMAS GERARD (US) | 2012-05-10 | — | — | US | disclosed |
| EP-2408790-A1 | METHODS FOR THE PREPARATION OF [2-(8,9-DIOXO-2,6-DIAZABICYCLO[5.2.0]NON-1(7)-EN-2-YL)ETHYL]PHOSPHONIC ACID AND PRECURSORS THEREOF | Wyeth LLC (US) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010108063-A1 | METHODS FOR THE PREPARATION OF [2-(8,9-DIOXO-2,6-DIAZABICYCLO[5.2.0]NON-1(7)-EN-2-YL)ETHYL]PHOSPHONIC ACID AND PRECURSORS THEREOF | WYETH LLC (US) | 2010-09-23 | — | — | WO | disclosed |
| EP-2195031-A1 | COMPOSITIONS AND METHODS EMPLOYING NMDA ANTAGONISTS FOR ACHIEVING AN ANESTHETIC-SPARING EFFECT | Wyeth a Corporation of the State of Delaware (US) | 2010-06-16 | — | — | EP | disclosed |
| US-20090061024-A1 | COMPOSITIONS AND METHODS EMPLOYING NMDA ANTAGONISTS FOR ACHIEVING AN ANESTHETIC-SPARING EFFECT | WYETH (US) | 2009-03-05 | — | — | US | disclosed |
| WO-2009029618-A1 | COMPOSITIONS AND METHODS EMPLOYING NMDA ANTAGONISTS FOR ACHIEVING AN ANESTHETIC-SPARING EFFECT | WYETH (US) | 2009-03-05 | — | — | WO | disclosed |
| US-20080114165-A1 | Methods for the Preparation of {2-[(8,9)-Dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl} Phosphonic Acid and Esters Thereof | WYETH (US) | 2008-05-15 | — | — | US | disclosed |
| US-7345032-B2 | alkylation of 1,3-diaminopropane or addition to diethyl vinylphosphonate, to form N-(3-aminopropyl)aminoethanephosphonic acid diethyl ester, which is condensed with a squarate compound to give drugs used as N-methyl-D-aspartic acid (NMDA) antagonists | WYETH (US) | 2008-03-18 | — | — | US | disclosed |
| EP-1675863-A2 | METHOD FOR THE PREPARATION OF {2-[8,9-DIOXO-2,6-DIAZA-BICYCLO[5.2.0]-NON-1(7)-EN-2-YL]ETHYL} PHOSPHONIC ACID AND ESTERS THEREOF | Wyeth (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005040176-A2 | METHODS FOR THE PREPARATION OF {2-[8,9-DIOXO-2,6-DIAZA-BICYCLO[5.2.0]-NON-1(7)-EN-2-YL]ETHYL}PHOSPHONIC ACID AND ESTERS THEREOF | WYETH (US) | 2005-05-06 | — | — | WO | disclosed |
| US-20050090470-A1 | Methods for the preparation of {2-[(8,9)-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl[ethyl} phosphonic acid and esters thereof | WYETH (US) | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090470-A1 | Methods for the preparation of {2-[(8,9)-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl[ethyl} phosphonic acid and esters thereof | PHOSPHO1, ENPP1, ENO1 | MEN1 1115/4885KMT2A 3650/4885CYP1A2 2844/4885 |
| US-20090061024-A1 | COMPOSITIONS AND METHODS EMPLOYING NMDA ANTAGONISTS FOR ACHIEVING AN ANESTHETIC-SPARING EFFECT | GRIN3A, GRIN1, GRIN2A | MEN1 4316/4885KMT2A 488/4885CYP1A2 4351/4885 |
| US-20120116074-A1 | METHODS FOR THE PREPARATION OF [2-(8,9-DIOXO-2,6-DIAZABICYCLO[5.2.0]NON-1(7)-EN-2-YL)ETHYL]PHOSPHONIC ACID AND PRECURSORS THEREOF | DERA, ENO1, PPIP5K2 | MEN1 2365/4885KMT2A 3175/4885CYP1A2 813/4885 |
| US-20080114165-A1 | Methods for the Preparation of {2-[(8,9)-Dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl} Phosphonic Acid and Esters Thereof | PHOSPHO1, ENPP1, ENO1 | MEN1 1109/4885KMT2A 3598/4885CYP1A2 2924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.